NYSE

Cardinal Health, Inc. (CAH)

726 Thanks from members

Cardinal Health (CAH) reported strong Q4 2026 results with 6% revenue growth to $63.7 billion and a 40% jump in non-GAAP diluted EPS to $2.91, driven by Pharmaceutical and Specialty Solutions, high-margin brand and generic performance, and a tariff refund benefit.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →